<DOC>
	<DOCNO>NCT00256997</DOCNO>
	<brief_summary>The purpose study evaluate risperidone long-acting injection ( antipsychotic medication ) versus oral antipsychotic schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) participant history poorly compliant take medication .</brief_summary>
	<brief_title>A Study Risperidone Long-Acting Injection Versus Oral Antipsychotics Schizophrenia Participants With History Being Poorly Compliant With Taking Their Medication</brief_title>
	<detailed_description>This Phase 4 , open-label ( people know identity intervention ) , multi-country multi-centric ( conducted one center ) study risperidone long-acting formulation versus oral ( mouth ) atypical antipsychotic participant Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text revision ( DSM-IV TR ) diagnosis schizophrenia currently treat oral antipsychotic medication . The duration study 2 year . All eligible participant randomly assign oral atypical antipsychotic ( risperidone , olanzapine , quetiapine , commercially available , aripiprazole amisulpride ) risperidone long-acting formulation . For risperidone long-acting formulation participant , study medication administer intramuscular ( muscle ) injection every 2 week dose 25 , 37.5 50 milligram ( mg ) . Oral supplementation current oral atypical antipsychotic require first 3 week follow initial injection dose increase . Dose increase make per product labeling . The primary measure effectiveness reduction percentage participant experience clinical exacerbation study 3 month . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) per Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text revision ( DSMIV TR ) Have least 2 hospitalization 2 clinical worsening symptom , past 2 year deteriorate adherence Is currently receive treatment antipsychotic per local product label guideline , history last 5 year satisfactory response ( minimum 6 week ) oral antipsychotic ( exclude clozapine ) On monotherapy antipsychotic treatment per local product label guideline , Baseline Female participant must surgically sterile , practice effective method birth control entry throughout study , negative urine pregnancy test screening study entry Participants primary DSMIV TR Axis I diagnosis schizophrenia Female participant currently pregnant breastfeed planning pregnancy within 2 year trial start Have serious , unstable untreated medical illness , vascular cardiovascular disease , history liver kidney disease , significant cardiac ( heart ) , pulmonary ( lung ) , gastrointestinal , endocrine , neurological ( pertain nervous system ) metabolic disturbance At significant risk suicide violence study start Evidence substance dependence ( except nicotine caffeine dependence ) accord DSMIV TR criterion diagnose last month prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal Consta</keyword>
</DOC>